The authors regret that post-publication, concerns were raised by a reader regarding this article (https://pubpeer.com/publications/2EAD25DB56BC0D75D911F9C63CB382).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jan Rekowski
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer
Clinical Research and Public HealthIn-Press PreviewClinical ResearchOncology Open Access | 10.1172/jci.insight.196505 Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer 1The Institute of Cancer Research, London, United Kingdom 2Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom 3Epic Sciences, San Diego, United States of America 4University Medical Center Hamburg-Eppendorf,...
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer - Nature Communications
|
By Inés Carnall Figueiredo, Inês Bravo Figueiredo, Wei Yuan, George Seed, Bora Gurel, Susana Miranda, Antonio J. Montero-Hidalgo, Wanting Zeng, Jan Rekowski, Mateus Crespo, Patricia C. Galipeau, Scott Wilkinson Verified, Fatima H Karzai, Cindy H Chau, Carleen Klumpp-Thomas, Amanda Swain, Florence Raynaud, Craig Thomas, Gavin Ha, William D Figg, Adam G. Sowalsky, Peter Nelson, Suzanne Carreira, Steven P. Balk, Nathan A. Lack
|
Nature
Verified
Abstract Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease requiring additional therapeutic strategies. MCL1, an anti-apoptotic BCL2 family member, promotes cancer-cell survival, but its role in mCRPC remains poorly understood. Here, we characterise MCL1 in multiple mCRPC biopsy cohorts and patient-derived models, assessing responses to MCL1 inhibition. MCL1 copy number gain (14%–34%) correlates with increased MCL1 expression and worse outcomes.
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial - Nature Medicine
Abstract Use of signal transduction inhibitors as single agents to treat cancer leads to resistance because of the plasticity of intracellular signaling, and combination therapy can overcome this. We describe the first-in-human trial of avutometinib (RAF–MEK clamp) and defactinib (focal adhesion kinase inhibitor) in patients with solid tumors. The trial met its primary endpoint and recommended a phase 2 dose and schedule.
Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy
Background: Surgical resection is considered to be of purely diagnostic value in aggressive lymphoma. Evidence for an impact on outcome is scant and restricted to retrospective observations. Methods: In the “Positron Emission Tomography-guided Therapy of Aggressive non-Hodgkin Lymphomas” (PETAL) trial, patients with a negative baseline positron emission tomography (PET) scan were documented in a prospective observational substudy.
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
Abstract The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage plasticity, and transformation to prostate cancers (PCs) that exhibit phenotypes of neuroendocrine or basal-like cells. The anti-apoptotic protein BCL2 is upregulated in neuroendocrine cancers and may be a therapeutic target for this aggressive PC disease subset.
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Research Methods & Reporting BMJ 2023; 383 doi: https://doi.org/10.1136/bmj-2023-076386 Cite this as: BMJ 2023;383:e076386 Christina Yap, professor of clinical trials biostatistics1, Jan Rekowski, principal statistician1, Moreno Ursino, research fellow and associate professor2 3 4 5, Olga Solovyeva, trial methodologist1, Dhrusti Patel, research assistant1, Munyaradzi Dimairo, senior research fellow6, Christopher J Weir, professor of medical statistics and clinical trials7, An-Wen Chan, Phelan...
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance - Nature
Abstract Inflammation is a hallmark of cancer1. In cancer patients, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio (NLR), associates with shorter survival and treatment resistance across malignancies and therapeutic modalities2-5. Whether myeloid inflammation drives prostate cancer progression in humans remain unclear.
Assessing the reporting quality of early phase dose-finding trial protocols: a methodological review
Summary Background The paradigm of early phase dose-finding trials has evolved in recent years. Innovative dose-finding designs and protocols which combine phases I and II are becoming more popular in health research. However, the quality of these trial protocols is unknown due to a lack of specific reporting guidelines. Here, we evaluated the reporting quality of dose-finding trial protocols.
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
4. Discussion In this study, we report that PD-L1, SOX2 IHC expression, and high TcellinfGEP scores are detected in 33%, 27%, and 26% of mCRPC biopsies, respectively, and are associated with shorter OS. To our knowledge, this is the first study reporting that these biomarkers, when studied in the mCRPC setting, are associated with OS.
Safety of Simultaneous Coronary Artery Bypass Grafting and Carotid Endarterectomy Versus Isolated Coronary Artery Bypass Grafting
Background and Purpose—The optimal operative strategy in patients with severe carotid artery disease undergoing coronary artery bypass grafting (CABG) is unknown. We sought to investigate the safety and efficacy of synchronous combined carotid endarterectomy and CABG as compared with isolated CABG.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jan
Contact Jan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack